Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
Michael Szarek(St. Michael's Hospital), R. Preston Mason(Brigham and Women's Hospital), Michael Miller(Clark University), Eliot A. Brinton(Inserm), Armando Lira Pineda(Amgen (United States)), Jean‐Claude Tardif(Montreal Heart Institute), Philippe Gabríel Steg(Mount Sinai Hospital), Patty W. Siri‐Tarino(Amarin (United States)), Steven Ketchum(Inserm), Terry A. Jacobson(Emory University), Richard L. Dunbar(Amarin (United States)), Christie M. Ballantyne(Baylor College of Medicine), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 8
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k